Previous 10 | Next 10 |
Data on CD19/BCMA dual-targeting FasTCAR-T GC012F showed 100% overall response rate (ORR) and 66.7% 6-month complete response (CR) rate among treated patients, all with diffuse large B-cell lymphoma (DLBCL) subtype Data on GC012F for treatment of relapsed/refractory multiple myeloma (...
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting PR Newswire Data on BCMA/CD19 dual-targeting FasTCAR-T GC012F showed 100% minimal residual disease (MRD) negativ...
2023-05-26 08:34:32 ET Onfolio Holdings ( ONFO ) +62% Completes Development of Generative AI Search Tool. Elevation Oncology ( ELEV ) +58% . Quhuo Limited ( QH ) +37% Sector Exceeded RMB12 Million in Sales During the Labor Day Holiday, Achieving Impre...
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, May 24, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment...
2023-05-21 09:05:00 ET Summary Shanghai’s LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million (including $55 million upfront) plus royalties on sales. Suzhou Coherent Biopharma closed a Series B+ round...
2023-05-15 11:22:10 ET Gracell Biotechnologies Inc. (GRCL) Q1 2023 Earnings Conference Call May 15, 2023 8:00 am ET Company Participants William Cao - Chairman, Chief Executive Officer Wendy Li - Chief Medical Officer Kevin Xie - Chief Financial Officer Con...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, May 15, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of ...
2023-05-15 07:19:53 ET Gracell Biotechnologies press release ( NASDAQ: GRCL ): Q1 GAAP EPS of -$0.07 beats by $0.08 . As of March 31, 2023, the Company had $186.0M in cash and cash equivalents and short-term investments. In addition, the Company had short-term borrowin...
Presenting longer-term follow-up data from investigator-initiated trial (IIT) evaluating BCMA/CD19 dual-targeting FasTCAR-T GC012F in relapsed/refractory multiple myeloma (RRMM) at 2023 ASCO and EHA2023 On track to commence a Phase 1b/2 clinical trial in U.S. and a Phase 1/2 clinical tria...
Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE) PR Newswire Gracell announces start of investigator-initiated trial to expand clinical evaluation of FasTCAR-T GC012F into autoimmune diseas...
News, Short Squeeze, Breakout and More Instantly...
Gracell Biotechnologies Inc. Company Name:
GRCL Stock Symbol:
NASDAQ Market:
Gracell Biotechnologies Inc. Website:
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell ...
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.49% on the day to $10.19. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of ...